Key facts
- This page summarizes Sandy Macrae's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2024, 17:11.
Sandy Macrae - 24 Feb 2024 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)
- Reporting relationship
- PRESIDENT, CEO AND DIRECTOR, Director
- Issuer ticker
- SGMO
- Reported as of
- 24 Feb 2024
- Net transaction value
- -$45,507
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2024, 17:11:45 UTC
- Prior SEC filing
- 24 Jan 2024
- Next SEC filing
- 29 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sandy Macrae filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 27 Feb 2024.
Change
- Previous filing in this sequence was filed on 24 Jan 2024.
- Current net transaction value: -$45,507.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGMO
transaction
Common Stock
Tax liability
- Transaction value
- $18,210
- Shares
- -16,115
- Change %
- -0.62%
- Price
- $1.13
- Shares after
- 2,576,361
- Date
- 24 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
SGMO
transaction
Common Stock
Tax liability
- Transaction value
- $27,297
- Shares
- -24,157
- Change %
- -0.94%
- Price
- $1.13
- Shares after
- 2,552,204
- Date
- 25 Feb 2024
- Ownership
- Direct
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents shares underlying the portions of RSU grants that vested on February 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
Footnote F2
Includes: (a) 23,210 shares resulting from the February 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 117,975 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 105,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (d) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.
Footnote F3
The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Footnote F4
Represents shares underlying the portions of RSU grants that vested on February 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
Footnote F5
Includes: (a) 29,280 shares resulting from the February 25, 2024 final vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 13,697 shares resulting from the February 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 84,000 shares will vest in successive equal quarterly installments through February 25, 2025, (c) 117,975 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (d) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.